Authorization

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc. (NASDAQ: MYGN) of the firm's investigation of possible disclosure violations concerning its GeneSight Psychotropic test, one of Myriad's most important products.
Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm
If you invested in Myriad before August 14, 2019and suffered losses or have information that may assist this investigation contact Hagens Berman:https://www.hbsslaw.com/investor-fraud/MYGNor contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailingMYGN@hbsslaw.com.The firm's investigation concernsA the accuracy of Myriad's statements regarding its GeneSight Psychotropic test, a kit intended to analyze how a patient's genes may affect their response to certain drugs.The Company has repeatedly promoted the quality and attributes of this new product, including most recently on August 1, 2019, when the Company announced insurer United Healthcare had decided to cover the test.A  In response, the price of Myriad shares steadily rose.But on August 13, 2019, Myriad shocked investors when it disclosed that the FDA had demanded changes to GeneSight.A  Although the Company claimed to have submitted a proposed solution to the FDA's demand, Myriad admitted that it did not know if regulators would accept the changes.A  Myriad also refused to discuss how increased regulatory scrutiny may impact sales of the test.This news drove the price of Myriad shares down $18.95, or down about 42%, on August 14, 2019."We're focused on investors' losses, when senior management received the FDA's demanded changes, and whether issues with GeneSightA should have been disclosed earlier," said Hagens Berman partner Reed Kathrein.Whistleblowers:Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. A Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. A For more information, call Reed Kathrein at 510-725-3000 or email MYGN@hbsslaw.com.About Hagens Berman
Hagens Berman is a national law with nine offices in eight cities around the country and eighty attorneys.A  The firm represents investors, whistleblowers, workers and consumers in complex litigation.A  More about the firm and its successes is located at hbsslaw.com. A For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.Contact:
Reed Kathrein, 510-725-3000A 
Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm
View original content to download multimedia:https://www.prnewswire.com/news-releases/hagens-berman-investigating-myriad-genetics-mygn-for-possible-disclosure-violations-investors-with-losses-should-contact-firm-300903997.htmlSOURCE Hagens Berman Sobol Shapiro LLP
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2019    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
30